No evidence that doping enhances athletic performance

No evidence that doping enhances athletic performance
Although use of recombinant human erythropoietin is prohibited among athletes because it reportedly enhances performance, there is no scientific evidence that it does so, according to a study published online Dec. 6 in the British Journal of Clinical Pharmacology.

(HealthDay)—Although use of recombinant human erythropoietin (rHuEPO) is prohibited among athletes because it reportedly enhances performance, there is no scientific evidence that it does so, according to a study published online Dec. 6 in the British Journal of Clinical Pharmacology.

Jules A.A.C. Heuberger, from Leiden University in the Netherlands, and colleagues reviewed 13 studies in the scientific and medical literature examining the effect of rHuEPO on .

The researchers found that no study specifically addressed . Most studies used forms of rHuEPO with half-lives similar to endogenous erythropoietin. Only eight studies were placebo controlled, and only five of these were reported to be double-blinded. Hemoglobin concentration, hematocrit, and increased after rHuEPO treatment. However, the authors note that the only parameters associated with enhanced performance are lactate threshold, respiratory compensation point, and work economy. In addition, published case reports have linked rHuEPO to adverse cardiovascular effects among cyclists.

"rHuEPO use in cycling is rife but scientifically unsupported by evidence and its use in sports is medical malpractice," Heuberger and colleagues conclude. "The situation with rHuEPO use in athletes is analogous to the many forms of non-evidence-based treatments that exist in medical practice and which by common opinion should be refuted or confirmed by good clinical trials with real life end points."

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

New study examines the validity of epo testing

Jun 26, 2008

Recombinant human erythropoietin (rHuEpo) is a genetically engineered hormone sometimes misused by high-performance athletes such as cyclists and marathon runners to boost their endurance. The potential misuse of the drug ...

The challenges and rewards of Paralympic medicine

Jul 05, 2012

In the Lancet paper, "Paralympic medicine," Nick Webborn of the British Paralympic Association and Peter Van de Vliet of the International Paralympic Committee Medical and Scientific Department, outline some of the issues ...

Recommended for you

Risk of antibiotic overuse in aged care settings

19 hours ago

Antibiotics are being overused in residential aged care facilities (RACFs), and more integrated efforts to improve antibiotic prescribing practices need to be introduced, researchers say. 

Ruconest approved for rare genetic disease

Jul 17, 2014

(HealthDay)—Ruconest has been approved by the U.S. Food and Drug Administration to treat hereditary angioedema, a genetic disease that leads to sudden and potentially fatal swelling of the hands, feet, limbs, face, intestinal ...

NIH system to monitor emerging drug trends

Jul 17, 2014

An innovative National Drug Early Warning System (NDEWS) is being developed to monitor emerging trends that will help health experts respond quickly to potential outbreaks of illicit drugs such as heroin and to identify increased ...

Novartis to use Google technology for eye care

Jul 15, 2014

Swiss drug developer Novartis will team with technology giant Google to develop a "smart" contact lens that could improve some eye conditions or help diabetics manage their disease.

User comments